Full-Time
Specialist Data Architect
Updated on 8/13/2026
Amgen
10,001+ employees
Biotech company creating biologic medicines
No salary listed
Hyderabad, Telangana, India
In Person
Bachelor's, Master's
 Data & Analytics (1) |
|---|
Get referred to Amgen
See people who can refer or advise you
- A Master’s degree with 4–6 years of experience in Computer Science, IT, or a related field, or a Bachelor’s degree with 6–8 years of experience in Computer Science, IT, or a related field, or a Diploma with 10–12 years of experience in Computer Science, IT, or a related field.
- Proficiency in creating conceptual, logical, and physical data models to represent information structures.
- Ability to interview and communicate with business subject matter experts to develop data models useful for their analysis needs.
- Knowledge of metadata standards, taxonomies, and ontologies to ensure data consistency and quality.
- Hands-on experience with big data technologies and platforms such as Databricks and Apache Spark, including PySpark and SparkSQL, and performance tuning on big data processing.
- Experience implementing data testing and data quality strategies.
- Excellent critical-thinking and problem-solving skills.
- Strong communication and collaboration skills.
- Develop and maintain conceptual, logical, and physical data models to support business needs.
- Contribute to and enforce data standards, governance policies, and best practices.
- Design and manage metadata structures to enhance information retrieval and usability.
- Maintain comprehensive documentation of the architecture, including principles, standards, and models.
- Evaluate and recommend technologies and tools that best fit solution requirements.
- Drive continuous improvement in the architecture by identifying opportunities for innovation and efficiency.
- Experience with graph technologies such as Stardog, AllegroGraph, and MarkLogic.
- Databricks certification is desired.
- Demonstrated awareness of how to function in a team setting.
- Demonstrated awareness of presentation skills.
Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.
Company Size
10,001+
Company Stage
IPO
Headquarters
Thousand Oaks, California
Founded
1980
Get referred to Amgen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 10% to $10.1 billion; guidance increased to $39.4 billion.
- Repatha, Evenity, and Uplizna grew 37%, 38%, and 90% in Q2 2026.
- Colorado’s Enbrel price cap stayed blocked on July 1, 2026, preserving legacy cash flows.
What critics are saying
- FDA sought Tavneos withdrawal in April 2026; approval integrity is under attack.
- Prolia and Xgeva fell 32% in Q2 2026 as biosimilars squeeze margins.
- If Tavneos disappears, Amgen loses $500 million annual sales and credibility with regulators.
What makes Amgen unique
- Repatha has outcomes data across primary and secondary prevention, rare in PCSK9s.
- Amgen’s six growth drivers delivered 26% growth and nearly 70% of Q2 sales.
- Hyderabad center opens in 2027, expanding seven-lab R&D with data-driven discovery.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Conference Attendance Budget
Company News
Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.
Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.
Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.
Amgen reported second quarter 2026 revenues of $10.1 billion, a 10% increase year-over-year. Product sales grew 9%, driven by volume growth across 22 products that achieved double-digit sales growth. The company's six key growth drivers grew 26% year-over-year, generating nearly 70% of second quarter product sales. GAAP earnings per share increased 65% to $4.37, whilst non-GAAP EPS rose 4% to $6.29. Notable product performance included Repatha sales increasing 37% to $953 million and EVENITY growing 38% to $714 million. The company generated $3.5 billion in free cash flow, compared to $1.9 billion in the prior year period. For full year 2026, Amgen expects total revenues between $38.2 billion and $39.4 billion, with non-GAAP EPS guidance of $22.30 to $23.50.
Amgen secured a preliminary injunction in early June 2026 blocking Colorado's proposed 70% price cap on Enbrel, its rheumatoid arthritis drug. The federal judge's decision preserves pricing flexibility for the legacy asset. However, the company initiated several voluntary Class II recalls of Corlanor and Sensipar batches in the US due to foreign substances and manufacturing deviations. While not yet financially material, the recalls highlight ongoing operational risks. Amgen's investment case depends on its diversified portfolio offsetting pricing pressure and biosimilar competition. The company projects revenue of $40.1 billion and earnings of $9.9 billion by 2029, requiring 2.5% annual revenue growth. Current 2026 guidance stands at $37.1–$38.5 billion in revenue. The combination of pricing relief and quality concerns presents investors with a rebalanced risk-reward profile for the biotech company.